Type 2 cytokines and scleroderma interstitial lung disease

被引:0
|
作者
Chiara Pellicano
Lorenzo Vantaggio
Amalia Colalillo
Krizia Pocino
Valerio Basile
Mariapaola Marino
Umberto Basile
Edoardo Rosato
机构
[1] Sapienza University of Rome,Department of Translational and Precision Medicine
[2] UOC of Clinical Pathology,Clinical Pathology Unit and Cancer Biobank, Department of Research and Advanced Technologies
[3] General Hospital San Pietro Fatebenefratelli,Department of Translational Medicine and Surgery
[4] IRCCS Regina Elena National Cancer Institute,undefined
[5] Università Cattolica del Sacro Cuore,undefined
[6] Fondazione Policlinico A. Gemelli IRCCS,undefined
[7] UOC Clinical Pathology DEA II Level,undefined
[8] Hospital Santa Maria Goretti-ASL Latina,undefined
来源
关键词
Systemic sclerosis; Interstitial lung disease; Th2 cytokines; Ground glass; CALIPER;
D O I
暂无
中图分类号
学科分类号
摘要
Interstitial lung disease (ILD) is a life-threatening complication of systemic sclerosis (SSc). Type 2 (Th2) cytokines play a pivotal role in airway disease. Study aim was to evaluate serum level of Th2 interleukin (IL) and chemokine in SSc-ILD. Serum levels of IL-4, IL-5, IL-11, IL-13, IL-21, IL-31 and CXCL-13 were measured by Bio-Plex Multiplex Immunoassays in 60 SSc patients and 20 healthy controls (HC). Pulmonary function tests with diffusion lung capacity for carbon monoxide (DLco) and high resolution computed tomography (HRCT) were performed in SSc patients. ILD is defined as fibrotic changes (ground glass, reticular and honeycombing), assessed by Computer-Aided Lung Informatics for Pathology Evaluation and Ratings (CALIPER) software, affecting at least 10% of the lungs. Serum levels of Th2 cytokines were higher in SSc patients than HC. A linear correlation was observed between ground glass and IL-13 (r = 0.342, p < 0.01), IL-21 (r = 0.345, p < 0.01), IL-31 (r = 0.473, p < 0.001), IL-4 (r = 0.863, p < 0.001), IL-5 (r = 0.249, p < 0.05) and peripheral blood eosinophils (r = 0.463, p < 0.001). We found a negative correlation between DLco and IL-4 (r =  − 0.511, p < 0.001) and peripheral blood eosinophils (r =  − 0.446, p < 0.001). In the logistic regression analysis, IL-4 is associated with DLco ≤ 60% of the predicted [OR 1.039 (CI 95%: 1.015–1.064), p < 0.001], whilst mRSS [OR 1.138 (CI 95%: 1.023–1.266), p < 0.05] and IL-4 [OR 1.017 (CI 95%: 1–1.034), p < 0.05] were associated with ILD. Th2 inflammation could play a key role in early phase of SSc-ILD.
引用
收藏
页码:3517 / 3525
页数:8
相关论文
共 50 条
  • [1] Type 2 cytokines and scleroderma interstitial lung disease
    Pellicano, Chiara
    Vantaggio, Lorenzo
    Colalillo, Amalia
    Pocino, Krizia
    Basile, Valerio
    Marino, Mariapaola
    Basile, Umberto
    Rosato, Edoardo
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (07) : 3517 - 3525
  • [2] TYPE 2 (TH2) CYTOKINES AND SCLERODERMA INTERSTITIAL LUNG DISEASE (SSC-ILD)
    Pellicano, C.
    Vantaggio, L.
    Colalillo, A.
    Pocino, K.
    Basile, V.
    Marino, M.
    Basile, U.
    Rosato, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 977 - 978
  • [3] Interstitial lung disease: is interstitial lung disease the same as scleroderma lung disease?
    Murray, Lynne A.
    Rubinowitz, Ami
    Herzog, Erica L.
    CURRENT OPINION IN RHEUMATOLOGY, 2012, 24 (06) : 656 - 662
  • [4] Interstitial lung disease in scleroderma
    White, B
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2003, 29 (02) : 371 - +
  • [5] Interstitial Lung Disease in Scleroderma
    Schoenfeld, Sara R.
    Castelino, Flavia V.
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2015, 41 (02) : 237 - +
  • [6] Cyclophosphamide for scleroderma interstitial lung disease
    Antoniu, Sabina A.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (03) : 393 - 395
  • [7] Targeting the NLRP3 inflammasome and associated cytokines in scleroderma associated interstitial lung disease
    Woo, Samuel
    Gandhi, Shifa
    Ghincea, Alexander
    Saber, Tina
    Lee, Chris J.
    Ryu, Changwan
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2023, 11
  • [8] Mycophenolate mofetil for interstitial lung disease in scleroderma
    Plastiras, S. C.
    Vlachoyiannopoulos, P. G.
    Tzelepis, G. E.
    RHEUMATOLOGY, 2006, 45 (12) : 1572 - 1572
  • [9] Coagulation and Autoimmunity in Scleroderma Interstitial Lung Disease
    Ludwicka-Bradley, Anna
    Silver, Richard M.
    Bogatkevich, Galina S.
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2011, 41 (02) : 212 - 222
  • [10] New developments in scleroderma interstitial lung disease
    Highland, KB
    Silver, RM
    CURRENT OPINION IN RHEUMATOLOGY, 2005, 17 (06) : 737 - 745